title: CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies.
abstract: Some evidence suggests that monoclonal antibodies (mAb) can induce an adaptive immune response against tumor cells ("vaccinal effect"). Recently, we have shown that an anti-CD137 mAb can enhance the "vaccinal effect" of an anti-tumor mAb (cetuximab), thereby transforming a passive, monoclonal, short-term immunotherapy into an active, polyclonal, long-lasting immune response.
authors.affiliation: CHU Rennes; Service Hématologie Clinique ; Rennes, France ; INSERM ; Rennes, France.
authors.forename: Roch
authors.initials: R
authors.lastname: Houot
authors.affiliation: Department of Medicine, Division of Oncology; Stanford University ; Stanford, CA USA.
authors.forename: Holbrook
authors.initials: H
authors.lastname: Kohrt
keywords: ADCC, antibody-dependent cellular cytotoxicity; Ag, antigens; CDC, complement-dependent cytotoxicity; CRC, colorectal cancer; DC, dendritic cells; FcR, Fc receptor; HN, head and neck; MHC, major histocompatibility complex; NK, natural killer; TCR, T cell receptor; antibody-dependent cell mediated cytotoxicity (ADCC); immunotherapy; mAb, monoclonal antibodies; monoclonal antibody; natural killer cells